GEN Exclusives

More »

GEN News Highlights

More »
Jan 3, 2008

Merck & Co. Agrees to Pay up to $702M for Addex’ Schizophrenia Compounds

  • Merck & Co. is paying $22 million upfront for Addex Pharmaceuticals’ preclinical compound to treat schizophrenia and other indications. Addex could receive an additional $670 million in milestone fees plus royalties.

    ADX63365 is a positive allosteric modulator (PAM) that targets the metabotropic glutamate receptor 5 (mGluR5). The deal also includes mGluR5 PAM backup compounds discovered by Addex.

    Merck could pay up to $455 million in research, development, regulatory, and sales milestones for the first product developed for two indications. The company will put forth up to another $225 million in development, regulatory, and sales milestones for a second product developed in two indications. Addex is also eligible to receive royalties on sales of any products resulting from this collaboration.

    Addex retains the option to copromote in certain EU countries. It will participate in the joint oversight committee for further development that will be led by Merck.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »